Universität zu Köln

Cramer, Paula ORCID: 0000-0003-4046-9922, Furstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Bottcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Bruggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2022). Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG) a multicentre, open-label, phase 2 trial. Lancet Haematol., 9 (10). S. E745 - 11. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Eichhorst, Barbara F., Bahlo, Jasmin, Maurer, Christian, Lange, Elisabeth, Koppler, Hubert, Kiehl, Michael G., Sokler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Kochling, Georg, Ploger, Christoph, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Dohner, Hartmut, Kneba, Michael, Wendtner, Clemens, Klapper, Wolfram, Kreuzer, Karl-Anton, Bottcher, Sebastian, Stilgenbauer, Stephan, Fink, Anna Maria and Hallek, Michael (2016). Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kramer, Isabelle, Stilgenbauer, Stephan, Dietrich, Sascha, Bottcher, Sebastian, Ritgen, Matthias, Bunjes, Donald, Zeis, Matthias, Stadler, Michael, Bittenbring, Joerg Thomas, Hegenbart, Ute, Hallek, Michael, Kneba, Michael, Schmitz, Norbert, Dohner, Hartmut and Dreger, Peter (2016). Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Landau, Dan A., Tausch, Eugen, Taylor-Weiner, Amaro N., Bottcher, Sebastian, Bahlo, Jasmin, Stewart, Chip, Edelmann, Jennifer, Kluth, Sandra, Mertens, Daniel, Kneba, Michael, Kless, Sabrina, Sougnez, Carrie, Fischer, Kirsten, Ritgen, Matthias, Gabriel, Stacey, Lander, Eric, Dohner, Hartmut ORCID: 0000-0003-2116-5536, Hallek, Michael, Getz, Gad, Neuberg, Donna, Stilgenbauer, Stephan and Wu, Catherine J. (2014). Subclonal Driver Mutations Predict Shorter Progression Free Survival in Chronic Lymphocytic Leukemia Following First-Line Chemo(immuno) Therapy: Results from the CLL8 Trial. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Bottcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020